Efficacy and Safety of Hetrombopag for Thrombocytopenia in Patients with Advanced Solid Tumors: A Retrospective Study

Table 2

14-day platelet increasing response rate in patients with different characteristics (n, %).

Variable	Number of patients (n)	Treatment response was achieved by (14 ± 2) days of hetrombopag treatment		χ^2	value
		Yes n (%)	No n (%)
Age
>60 years	36	22 (61.1%)	14 (38.9%)	1.250	0.264
≤60 years	24	18 (75.0%)	6 (25.0%)
Gender
Male	34	20 (58.8%)	14 (41.2%)	2.172	0.141
Female	26	20 (76.9%)	6 (23.1%)
Baseline platelet count
50 × 10^9/L∼75 × 10^9/L (grade 2 thrombocytopenia)	37	27 (73.0%)	10 (27.0%)	2.103	0.349
25 × 10^9/L∼50 × 10^9/L (grade 3 thrombocytopenia)	17	9 (52.9%)	8 (47.1%)
<25 × 10^9/L (grade 4 thrombocytopenia)	6	4 (66.7%)	2 (33.3%)
Antitumor treatment regimen
Chemotherapy only	13	9 (69.2%)	4 (30.8%)	3.906	0.272
Targeted/targeted + chemotherapy only	12	10 (83.3%)	2 (16.7%)
Immune/immune + chemotherapy only	17	12 (70.6%)	5 (29.4%)
Targeting + immunization/targeting + immunization + chemotherapy	18	9 (50.0%)	9 (50.0%)
Prior platelet increasing therapy
rhTPO	36	24 (66.7%)	12 (33.3%)	0.150	0.928
TPO-RA (avatrapopag, eltrombopag)	4	3 (75.0%)	1 (25.0%)
None	20	13 (65.0%)	7 (35.0%)
Hetrombopag therapeutic dose
2.5 mg	11	8 (72.7%)	3 (27.3%)	0.223	0.637
5 mg	49	32 (65.3%)	17 (34.7%)

rhTPO, recombinant human thrombopoietin; TPO-RA; thrombopoietin receptor agonist.